Come si colloca il rapporto ACER di PB rispetto ai suoi colleghi?

ACER ha un patrimonio netto negativo e un rapporto Price-To-Book ( -0.6 x) rispetto alla media dei peer ( 1.7 x).

Come si colloca il ACER's PB Ratio rispetto ad altre aziende del US Pharmaceuticals settore?

ACER ha un patrimonio netto negativo e un rapporto Price-To-Book ( -0.6 x) rispetto alla media del settore US Pharmaceuticals ( 1.8 x).

Qual è il ACER PB Ratio rispetto al suo Fair PB Ratio? Si tratta del PB Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

Dati insufficienti per calcolare il Fair Ratio di ACER Price-To-Book per l'analisi di valutazione.

Qual è il prezzo equo di ACER se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

Dati insufficienti per calcolare il valore equo di ACER ai fini dell'analisi di valutazione.

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Dati insufficienti per mostrare la previsione dei prezzi.

Acer Therapeutics (OTCPK:ACER) - Prezzo delle azioni, notizie e analisi

ACER Panoramica delle azioni

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Maggiori dettagli

ACER analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	0/6
Dividendi	0/6

Premi

Si prevede che gli utili cresceranno del 66.22% all'anno

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Patrimonio netto negativo

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Ha meno di 1 anno di pista di cassa

+ 2 più rischi

Acer Therapeutics Inc. Concorrenti

DURECT

NasdaqCM:DRRX

US$31.3m

MIRA Pharmaceuticals

NasdaqCM:MIRA

US$21.9m

ProPhase Labs

NasdaqCM:PRPH

US$18.4m

Cognition Therapeutics

NasdaqGM:CGTX

US$17.2m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Acer Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.80
Massimo di 52 settimane	US$4.56
Minimo di 52 settimane	US$0.55
Beta	0.44
1Variazione di 1 mese	-2.73%
Variazione a 3 mesi	21.88%
Variazione di 1 anno	-30.04%
3Variazione a 3 anni	-70.42%
Variazione a 5 anni	-96.75%
Variazione dall'IPO	-91.99%

Notizie e aggiornamenti recenti

Recent updates

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Oct 05

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Aug 12

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Jul 28

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Feb 25

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders

Dec 22

Rendimenti per gli azionisti

	ACER	US Pharmaceuticals	US Mercato
7D	-5.4%	1.6%	2.2%
1Y	-30.0%	9.9%	31.6%

Ritorno vs Industria: ACER ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 9.9 % nell'ultimo anno.

Rendimento vs Mercato: ACER ha avuto una performance inferiore al mercato US che ha registrato un rendimento 31.6 % nell'ultimo anno.

Volatilità dei prezzi

Is ACER's price volatile compared to industry and market?
ACER volatility
ACER Average Weekly Movement	32.3%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di ACER è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di ACER è aumentata da 23% a 32% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1991	30	Chris Schelling	www.acertx.com

Acer Therapeutics Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Acer Therapeutics con la sua capitalizzazione di mercato?
ACER statistiche fondamentali
Capitalizzazione di mercato	US$19.68m
Guadagni(TTM)	-US$38.76m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.5x

Rapporto P/E

ACER è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ACER Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$38.76m
Guadagni	-US$38.76m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.58
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	-96.4%

Come si è comportato ACER nel lungo periodo?

Vedi performance storica e confronto

ACER Panoramica delle azioni

Premi

Analisi del rischio

Acer Therapeutics Inc. Concorrenti

NasdaqCM:DRRX

US$31.3m

NasdaqCM:MIRA

US$21.9m

NasdaqCM:PRPH

US$18.4m

NasdaqGM:CGTX

US$17.2m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Acer Therapeutics Inc. Files Form 15

Acer Therapeutics Inc. Announces Executive Changes

Nasdaq to Delist the Securities of Acer Therapeutics

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index

Recent updates

Acer Therapeutics Inc. Files Form 15

Acer Therapeutics Inc. Announces Executive Changes

Nasdaq to Delist the Securities of Acer Therapeutics

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Acer Therapeutics Receives a Letter from Nasdaq Indicating the Company Is Not in Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Acer Therapeutics Inc. Receives Non-Compliance Notice From Nasdaq

Acer Therapeutics Announces Full Enrollment of Phase 2A Trial of Acer-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Acer Therapeutics Inc. Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

Acer Therapeutics Compliant with All Nasdaq Listing Criteria

Acer Therapeutics Inc. announced that it has received $1.5 million in funding

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.23 loss in 3Q 2021)

Insufficient new directors

Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)

Acer Therapeutics Inc. Announces Receipt of Notice of Allowance of US Patent Application Covering Kit Comprising Phenylbutyrate and Sodium Benzoate

Acer Therapeutics Inc. Announces Expansion of Acer-801 (Osanetant) Development Indications to Include Post-Traumatic Stress Disorder

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

First half 2022 earnings released: US$0.80 loss per share (vs US$0.54 loss in 1H 2021)

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Acer Therapeutics Inc. Resubmittes the ACER-001 New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders

Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Acer Therapeutics Not Yet Received Decision from the U.S. Food and Drug Administration on ACER-001

Acer Therapeutics Receives a Letter from the Listing Qualifications Department Staff of the Nasdaq Stock Market Regarding Minimum Market Value of Listed Securities

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Acer Therapeutics Inc. Provides an Update on the Recent Corporate Developments

Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Insufficient new directors

Acer Therapeutics Inc., Annual General Meeting, May 20, 2022

Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Acer Therapeutics’ EDSIVO Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome

Acer Therapeutics Regains Compliance with Nasdaq Listing Standard

Acer Therapeutics Enrolls First Patient in Its Phase 2A Clinical Trial of Acer-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Consensus revenue estimates fall by 29%

Acer Therapeutics Inc. Announces Appointment of Adrian Quartel as Chief Medical Officer

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

No longer forecast to breakeven

Acer Therapeutics Inc. Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Consensus forecasts updated

Acer Therapeutics Plans Clinical Trial for Edsivo Following Type B FDA Meeting

Acer Expands Its Predator Gaming Portfolio with Three New HDR Monitors

Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA

Consensus revenue estimates increase to US$8.00m

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

Acer Therapeutics Inc. Announces Update on Settlement of Derivative Suits

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Acer Therapeutics Inc. Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions

Relief Therapeutics and Acer Therapeutics Sign Option Agreement to Pursue a Potential Collaboration and License Arrangement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

New 90-day high: US$3.85

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders